Background: Tamsulosin remains the single most popular uroselective alpha adrenoceptor antagonist approved for the treatment of lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH). Over the last 3 decades, the utilization of tamsulosin has extended to conditions beyond its original indication. To identify potential changes to prescribing patterns and the extent of tamsulosin use for conditions beyond its original indication, we evaluated tamsulosin dispensing patterns in the United States using a large, multi-payer claims database.
Introduction
The histological prevalence of benign prostatic hyperplasia (BPH) increases steadily with age, affecting 10% of men aged 30-40 years and 80-90% of men aged 70-80 years (1). Many, but not all men with histologically confirmed BPH develop lower urinary tract symptoms (LUTS) (1). Over the last 30 years, alpha-adrenergic sympathomimetic blocking agents have been the firstline treatment of bothersome, moderate-to-severe LUTS attributable to BPH (male LUTS) (2, 3) . However, for much of that time, initiation of alpha-blockers was an arduous process, often requiring dose adjustments, considerations regarding timing of administration, and frequent blood pressure monitoring to avoid orthostatic hypotension (4) (5) (6) . The introduction in 1997 of tamsulosin (7)-a thirdgeneration alpha 1 adrenoceptor antagonist that targets the alpha 1A -receptors expressed on the prostate stromal smooth muscle cells (8)-represented a breakthrough in the medical treatment of male LUTS because of its comparable efficacy and improved side effect profile over prior nonselective alpha-blockers (9, 10) . Tamsulosin facilitated the treatment of male LUTS by urologists and subsequently, was readily available for dispensation by many medical specialties (8) . Despite the emergence of several newer uroselective alpha-blockers, tamsulosin is the most popular of these agents (11) . It is also the preferred alpha 1A antagonist available in the Veterans Affairs medical system (12, 13) , as well as commercial insurance plans (14) .
In the United States (US), urologists have traditionally been the gatekeepers for the medical management of male LUTS, providing higher dispensation of BPH medications than other medical specialties (15) . Although tamsulosin was approved by the US Food and Drug Administration (FDA) for the treatment of the signs and symptoms of BPH (7) , with the changing healthcare landscape and evaluation of alpha-blockers for the treatment of urolithiasis (16) , prostatitis (17) , neurogenic bladder (18), and even female voiding dysfunction (19) , it may now be dispensed to men and women for conditions other than male LUTS.
To identify potential changes to prescribing patterns and the extent of tamsulosin use for conditions beyond its original indication, we evaluated tamsulosin dispensing patterns in the US, using a large, multi-payer claims database. Specifically, we aimed to identify and characterize individuals who were dispensed tamsulosin, particularly for the first time, and men who received a BPH diagnosis.
Additionally, we sought to characterize the health care professional (HCP) specialties which prescribed tamsulosin, as well as pre-existing comorbid conditions and newly diagnosed conditions of interest in men initiating tamsulosin for the first time.
Methods

Data source
Claims data were retrieved from the IMS PharMetrics Plus™ database (20)-a large, multi-payer Health Insurance Portability and Accountability Act-compliant database containing adjudicated medical and pharmacy claims from over 55 US health plans. The interested reader can find additional details about the database, study design and assessments in a Supplementary file.
Study design and assessments
This retrospective, exploratory analysis comprised 2 main time periods ( Figure 1) : a 12-month selection period (October 1, 2012 to September 30, 2013) for identifying men or women who were dispensed tamsulosin or men who received a BPH diagnosis [documented International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) 600.xx code] and an 18-month analysis period [12 months before (look-back period) and 6 months after (look-forward period) tamsulosin initiation or first documentation of BPH diagnosis (index dates)]. These diagnostic codes were utilized as they are most specific to BPH-related diagnoses. Additionally, the rationale for investigating tamsulosin, 1 of 3 uroselective agents available in the US, is that it has emerged as the most popular of these agents.
Patients
Patients dispensed tamsulosin or diagnosed with BPH during the selection period were assigned to 1 or both the cohorts. The first cohort (tamsulosin users) comprised men or women who were dispensed tamsulosin during the selection period and were further categorized as continuing or new tamsulosin users. The second cohort comprised men who received a BPH diagnosis during the selection period and were further categorized based on existing or newly diagnosed BPH.
Additional information on methods is included in the Supplementary file.
Since alpha-blockers may affect blood pressure and can increase the possibility of orthostatic hypotensive events, especially after the first dose (21, 22) , the proportion of male new tamsulosin users who received a hypotension diagnosis within 1 month of tamsulosin initiation was determined. Occurrence of other targeted comorbidities in these men was also evaluated. Overall, 98,371 (68.6%) men with newly diagnosed BPH had ≥1 targeted comorbidity in the 12 months before the BPH index date ( Table 3) , and 640 men received a hypotension diagnosis code ( Table 4) .
Results
Tamsulosin users
As mentioned above, men receiving tamsulosin may be at an increased risk of orthostatic hypotensive events. To further understand the potential for a first-dose effect, the proportion of men with a hypotension diagnosis code within 1 month of the BPH index date was determined, and occurrence of other targeted comorbidities was assessed. Relatively few [640/143,444 (0.4%)] men with newly diagnosed BPH received a diagnosis of hypotension within 1 month of the BPH index date. The most frequently recorded other targeted comorbidities among these men were hypertension (69.8%), dyslipidemia (55.8%), and heart disease/disorder (50.6%).
Discussion
In this retrospective, claims-based analysis, we identified men and women who were dispensed tamsulosin and men who were diagnosed with BPH over a 12-month period. We used the IMS PharMetrics Plus™ medical claims database, which captures a comprehensive clinical picture and provides a temporal snapshot of typical national healthcare delivery (20) .
Although tamsulosin is approved for the treatment of male LUTS, it has been evaluated for the treatment of other conditions such as neurogenic bladder, ureteral stones, and even for voiding dysfunctions in women (18, 19, 23, 24) . Results of the current analysis show that 11.1% of all tamsulosin users and 18.4% of new tamsulosin users were women. Kidney stones were the most common (73.4%) targeted comorbidity identified in women during the 12 months before tamsulosin initiation, and emergency medicine physicians most often initiated tamsulosin use in women.
Interestingly, tamsulosin was dispensed commonly to men without a reported BPH diagnosis. For example, tamsulosin was dispensed before BPH was diagnosed in 61.1% of all men with newly diagnosed BPH. Further, almost half of the men dispensed tamsulosin-44.6% overall and 48.3% of new tamsulosin users-did not have a BPH diagnosis during the entire 18-month analysis period. Among male new tamsulosin users without a BPH diagnosis in the 12 months before tamsulosin initiation, most (87.1%) did not record a subsequent BPH diagnosis within 6 months of their initial tamsulosin dispensation. Several factors may contribute to these findings. A BPH diagnosis could have been documented >12 months before initiation of tamsulosin, a code for LUTS may have been entered instead of a code for BPH, the presence of comorbidities may have confounded diagnosis code entry in the submitted claim, and/or, as reported in previous studies (18, 19, 23, 24) , tamsulosin may have been dispensed for conditions other than BPH. In this analysis, 2 different treatment patterns were observed among new tamsulosin users. Consistent with the chronic nature of BPH, over one-third (36.6%) of men with a BPH diagnosis had a 151-to 180-day supply, suggestive of long-term use. Interestingly, 14.9% of men without a BPH diagnosis had a 151-to 180-day supply, suggesting that tamsulosin was used for a chronic condition-most likely BPH-and supports the finding that physicians might not be coding BPH even if it is present and they are treating it. The other two-thirds (63.6%) had a ≤30-day supply, suggestive of episodic use. Traditionally, urologists were considered the primary caregivers for patients with LUTS attributable to BPH because managing these patients was primarily a surgical endeavor (25) . However, PCPs became more involved in BPH diagnosis and management once efficacious pharmacological options became available in the 1990s (15, 26, 27) . In a US survey conducted in 1998, half of the men with symptomatic BPH initially visited PCPs (25%) or internal medicine specialists (24%), although first-care management was provided by urologists in 37% cases (15) . Results from a retrospective cohort study using medical claims from a large, non-profit, managed care organization showed that despite accounting for less than one-third of the office visits for management of BPH, patients were twice as likely to be treated with medical therapy by urologists than PCPs (28) .
The healthcare landscape seems to be changing, however, and PCPs are now actively prescribing alpha-blockers such as tamsulosin. Results of an observational study based on 2004-2005 BPH Registry data showed that significantly more men consulting PCPs than urologists (51.6% vs. 43.0%; P<0.001) used alpha-blockers (e.g., alfuzosin and tamsulosin) (29) . In the present analysis, PCPs initiated tamsulosin in approximately 31.6% male new tamsulosin users, while urologists and emergency medicine physicians initiated tamsulosin in approximately 18.0% and 11.5% male new tamsulosin users, respectively. Interestingly, only 25.5% of men with newly diagnosed BPH were dispensed tamsulosin during the analysis period. Under-treatment of men with BPH is well recognized; in prior US and multinational surveys, approximately 10% of symptomatic men received relevant medications for BPH/LUTS (30, 31) . Nonetheless, the low rate of prescribing could reflect other factors, such as treatment with alternative drugs or procedures, the presence of mild symptoms not necessitating treatment, or patient preference for no treatment.
Comorbidities are frequently age related and many are correlated with BPH. Therefore, we evaluated targeted comorbidities present during the 12 months before tamsulosin initiation among male new tamsulosin users. Most (85.3%) male new tamsulosin users had ≥1 targeted comorbidity before starting tamsulosin-most frequently hypertension, dyslipidemia, kidney stones, heart disease/ disorder, and diabetes. Although not assessed in this analysis, these men were likely taking medications for some or all of their comorbid conditions. Despite comorbidities and presumed polypharmacy, tamsulosin was initiated. Similarly, many (68.6%) men with newly diagnosed BPH had ≥1 targeted comorbidity during the 12 months before being diagnosed, and most conditions of interest were identified before the BPH diagnosis was made or tamsulosin treatment was initiated.
Alpha-blockers are generally safe (10); however, they are associated with the occurrence of orthostatic hypotension, especially following the first dose (21, 22) . Additionally, concomitant use of pharmacological agents for comorbid conditions, especially agents with known hypotensive effects, can potentially increase the risk of hypotension. In clinical trials, reports of hypotensive adverse events with tamsulosin use were usually mild and transient (32, 33) . Signs and symptoms of orthostasis were detected more frequently in patients treated with tamsulosin than placebo; however, incidence rates were low for symptomatic postural hypotension (0.2-0.4% vs. 0.0%), syncope (0.2-0.4% vs. 0.6%), and vertigo (0.6-1.0% vs. 0.6%); incidence of dizziness was 15-17% vs. 10% (7) . In a meta-analysis of alpha-blockers, rates of orthostatic hypotension associated with tamsulosin and alfuzosin use were comparable with that of placebo (1% each) (9) . In the present analysis, 0.4% of male new tamsulosin users were diagnosed with hypotension within 1 month of starting tamsulosin. Of note, cardiovascular comorbidities were more common in these men than in the overall population.
In a previous retrospective cohort study that also employed the IMS PharMetrics Plus™ database, a temporal association between tamsulosin use and severe hypotension requiring hospitalization during the first 2 months after starting or restarting tamsulosin was reported among men aged 40-85 years (21) . However, half [165,292/324,255 (51.0%)] of the men had ≥19 prescriptions dispensed in the 6-month period before starting tamsulosin; dispensed medications included concomitant antihypertensive agents (ranging from 20.8% for calcium channel blockers to 43.7% for angiotensin II receptor blockers and angiotensinconverting enzyme inhibitors). Although the authors included an assessment of the Charlson comorbidity score, they did not report on the prevalence of hypertension and other common significant age-related comorbidities often seen in men presumed to have BPH. A full understanding of the association between hypotension and tamsulosin should consider the effect of comorbid conditions and their pharmacologic management.
While informative in many respects, this retrospective analysis has some limitations, mainly associated with the database used and the study design. The IMS PharMetrics Plus™ database primarily represents privately insured patients aged ≤65 years; therefore, individuals >65 years are underrepresented in this analysis. Additionally, the data are intended for reimbursement and the quality of the claims is dependent on the accuracy of reporting and coding (34) . Therefore, the number of patients with a BPH diagnosis and those with comorbidities may not have been captured accurately in the database. The association between the drug dispensed and the diagnosis or reason for its prescription is not provided. An understanding of the dynamic circumstances that affect the assignment of diagnostic codes is needed when interpreting findings, as large variations in coding and reporting, such as change in codes and addition of new codes, can occur among clinicians and over time. Although dispensation and day supply data were captured and analyzed, these parameters may be influenced by the services provided (i.e., insurance company) and may not represent actual tamsulosin use.
Conclusions
In this retrospective analysis of a large cohort of privately insured patients, we found that although tamsulosin is approved for the signs and symptoms of BPH (7) , treatment initiation with tamsulosin was observed among men and women, which suggests that HCPs seem comfortable prescribing tamsulosin for conditions other than BPH. Among men dispensed tamsulosin, many did not have a BPH diagnosis before receiving tamsulosin. Most men dispensed tamsulosin had ≥1 pre-existing comorbidity and were presumably receiving corresponding concomitant medications, suggesting that physicians were comfortable prescribing tamsulosin in the presence of comorbidity and polypharmacy. Furthermore, PCP and emergency medicine physicians primarily prescribed tamsulosin to men and women, respectively; however, urologists primarily diagnosed BPH. Importantly, the incidence of reported hypotension within 1 month of starting tamsulosin treatment was low, which supports the findings from randomized controlled trials that suggest that the firstdose orthostatic hypotensive adverse effect of tamsulosin is usually transient and mild in nature. In conclusion, the results of this exploratory analysis have important implications for further retrospective research into the use of this pharmaceutical agent.
